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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 76, Revision 1 
(FGE.76Rev1)  
Consideration of sulphur-containing heterocyclic compounds evaluated by 
JECFA (59th meeting) structurally related to thiazoles, thiophene, thiazoline 
and thienyl derivatives from chemical group 29 and miscellaneous 
substances from chemical group 30 evaluated by EFSA in FGE.21Rev31 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present opinion concerns a group of 
26 sulphur-containing heterocyclic compounds evaluated by the JECFA at the 59th meeting in 2008. This 
revision is made due to the inclusion of one additional substance, 5-methyl-2-thiophenecarbaldehyde [FL-no: 
15.004], cleared for genotoxicity concern in FGE.224. Additionally, new toxicity data have become available for 
5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113]. Since publication of FGE.76, one 
substance, thiazole [FL-no: 15.028], is no longer supported by Industry for use as a flavouring substance in 
Europe and will therefore not be considered any further. The substances were evaluated through a stepwise 
approach that integrates information on structure-activity relationships, intake from current uses, toxicological 
threshold of concern, and available data on metabolism and toxicity. The Panel agrees with the application of the 
Procedure as performed by the JECFA for 21, [FL-no: 15.001, 15.002, 15.004, 15.008, 15.011, 15.013, 15.014, 
15.015, 15.016, 15.017, 15.019, 15.020, 15.021, 15.022, 15.026, 15.027, 15.033, 15.035, 15.109, 15.113 and 
16.027], of the 26 substances considered in this FGE and agrees with the JECFA conclusion, “No safety concern 
at estimated levels of intake as flavouring substances” based on the MSDI approach. For five substances [FL-no: 
15.005, 15.018, 15.029, 15.030 and 15.032], the Panel could not conclude on their safety when used as 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2013-00222, EFSA-Q-2013-00223, adopted on 24 
October 2013. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, 
Alessandro Di Domenico, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter 
Jany, Martine Kolf-Clauw, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de Fatima Tavares 
Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu   
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Trine Husøy, John 
Christian Larsen, Wim Mennes, Gerard Mulder and Harriet Wallin for the preparatory work on this scientific opinion and 
the hearing experts: Vibe Beltoft, Pia Lund and Karin Nørby and EFSA staff: Annamaria Rossi and Kim Rygaard Nielsen 
for the support provided to this scientific opinion. 
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flavouring substances, as these substances could not be evaluated because of concern with respect to 
genotoxicity. Besides the safety assessment of these flavouring substances, the specifications for the materials of 
commerce have also been considered and for all 26 substances, the information is adequate. 
© European Food Safety Authority, 2013 
KEY WORDS 
flavouring safety, sulphur-containing heterocyclic compounds, thiazoles, thiophene, thiazoline and 
thienyl derivatives, 59th JECFA meeting, FGE.21 
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SUMMARY 
Following a request from the European Commission, the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion to provide 
scientific advice to the Commission on the implications for human health of chemically defined 
flavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was 
requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) 
evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation 
is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These flavouring 
substances are listed in the Register, which was adopted by Commission Decision 1999/217/EC and 
its consecutive amendments. 
In Flavouring Group Evaluation 76 (FGE.76), the EFSA considered 26 sulphur-containing 
heterocyclic compounds evaluated by the JECFA at its 59th meeting. Since publication of FGE.76, one 
substance, thiazole [FL-no: 15.028], is no longer supported by Industry for use as a flavouring 
substance in Europe and will therefore not be considered any further. The present revision is made due 
to inclusion of one additional substance, 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004], cleared 
for genotoxicity concern in FGE.224. Additionally, new toxicity data have become available for 5,6-
dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113]. Therefore, the present 
revision of FGE.76, FGE.76Rev1, considers 26 flavouring substances evaluated by the JECFA. 
The Panel concluded that all 26 Register substances in the JECFA flavouring group of sulphur-
containing heterocyclic compounds are structurally related to the 59 thiazoles, thiophenes, thiazoline 
and thienyl derivatives from chemical group 29 and miscellaneous substances from chemical group 30 
evaluated by EFSA in the Flavouring Group Evaluation 21, Revision 3 (FGE.21Rev3). 
In the previous version of FGE.76, the Panel considered that for the substances [FL-no: 15.109 and 
15.113] no adequate NOAELs were available. Since then a 90-day study has become available for 5,6-
dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113] providing a NOAEL to 
establish adequate margins of safety for the substance, as well as for the structurally related 2,4,6-
trimethyldihydro-1,3,5(4H)-dithiazine [FL-no: 15.109]. 
The Panel agrees with the application of the Procedure as performed by the JECFA for 21 of the 26 
substances considered in this FGE. Three of the remaining five substances, 2-(sec-butyl)-4,5-dimethyl-
3-thiazoline [FL-no: 15.029], 4,5-dimethyl-2-ethyl-3-thiazoline [FL-no: 15.030] and 4,5-dimethyl-2-
isobutyl-3-thiazoline [FL-no: 15.032], were considered by the Panel to have genotoxic potential in 
vitro, and therefore the Panel decided that the Procedure should not be applied to these three 
flavouring substances until adequate in vivo genotoxicity data become available. Additionally, the 
Panel noted the presence of a terminal conjugated double bond in the substances 2,4-dimethyl-5-
vinylthiazole [FL-no: 15.005] and 4-methyl-5-vinylthiazole [FL-no: 15.018] which raised concern for 
genotoxicity. The Panel concluded that the Procedure should not be applied to these two substances 
either until additional data become available. 
Thus, the Panel agreed that the Procedure can be applied to 21 of the 26 JECFA-evaluated substances 
[FL-no: 15.001, 15.002, 15.004, 15.008, 15.011, 15.013, 15.014, 15.015, 15.016, 15.017, 15.019, 
15.020, 15.021, 15.022, 15.026, 15.027, 15.033, 15.035, 15.109, 15.113 and 16.027], whereas five 
substances [FL-no: 15.005, 15.018, 15.029, 15.030 and 15.032] cannot be evaluated using the 
Procedure until additional data become available. 
For all 26 substances, the JECFA evaluation is based on MSDI values derived from production figures 
from the EU. 
For all 21 substances evaluated through the Procedure use levels are needed to calculate the modified 
Theoretical Added Maximum Daily Intake (mTAMDI) in order to identify those flavouring substances 
that need more refined exposure assessment and to finalise the evaluation. 
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In order to determine whether the conclusion for the 26 JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity are available for all 26 the JECFA 
evaluated substances.  
Thus, for five substances [FL-no: 15.005,  15.018,  15.029, 15.030 and 15.032] the Panel could not 
conclude on their safety when used as flavouring substances, as these substances could not be 
evaluated because of concern with respect to genotoxicity. 
For the remaining 21 of the 26 JECFA-evaluated sulphur-containing heterocyclic compounds [FL-no: 
15.001, 15.002, 15.004, 15.008, 15.011, 15.013, 15.014, 15.015, 15.016, 15.017, 15.019, 15.020, 
15.021, 15.022, 15.026, 15.027, 15.033, 15.035, 15.109, 15.113 and 16.027] the Panel agrees with the 
JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances” based on 
the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA concluded that a genotoxic potential of the two α,β-unsaturated thiophenes in FGE.224 could 
not be ruled out. Information on 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004] has now been 
submitted by the European Flavour Association. 
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substance in FGE.76. 
EFSA concluded in FGE.76 that for two substances [FL-no: 15.109 and 15.113], there are insufficient 
data available to provide margins of safety from their use as flavouring substances and that additional 
toxicity data are needed. 
The requested information on one representative material, 5,6-dihydro-2,4,6,tris(2-methylpropyl)-4H-
l,3,5-dithiazine [FL-no: 15.113] has now been submitted by the European Flavour Association. This 
information is intended to cover the re-evaluation of this substance and of one substance from FGE.76 
(2,4,6-trimethyldihydrol, 3,5(4H)-dithiazine [FL-no: 15.109]).  
The Commission asks EFSA to evaluate this new information as well.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004], 5,6-dihydro-2,4,6,tris(2-
methylpropyl)-4H-l,3,5-dithiazine [FL-no: 15.113] and 2,4,6-trimethyldihydrol, 3,5(4H)-dithiazine 
[FL-no: 15.109] in accordance with Commission Regulation (EC) No 1565/2000. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
 certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No  
 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Official Journal of the European  
 Communities 31.12.2008, L 354/34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting  
 the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the  
 Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and  
 repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. Official Journal of the  
 European Communities 2.10.2012, L 267, 1-161.OJ L 267, 2.10.2012, p. 1. 
6  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an  
 evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities  
 19.7.2000, L 180, 8-16. 
Flavouring Group Evaluation 76, Revision 1
 
EFSA Journal 2013;11(11):3455 8
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the Opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram (µg)/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
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Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE  
The JECFA has evaluated a group of 30 flavouring substances consisting of sulphur-containing 
heterocyclic compounds (JECFA, 2002a). 
In FGE.76, which covered a group of 26 of the 30 JECFA-evaluated substances, the Panel concluded 
that for six substances [FL-no: 15.005, 15.018, 15.028, 15.029, 15.030 and 15.032], the Procedure 
should not be applied until adequate genotoxicity data become available. For eight other substances, 
European exposure information (MSDI) was not available [FL-no: 15.002, 15.005, 15.008, 15.027, 
15.029, 15.030, 15.109 and 15.113]. In addition, the Panel considered that for the substances [FL-no: 
15.109 and 15.113], there were insufficient data available to provide margins of safety from their use 
as flavouring substances and that additional toxicity data were needed. 
 
Since the publication of FGE.76, Industry has informed that thiazole [FL-no: 15.028] is no longer 
supported for use as flavouring substances in Europe (EFSA, 2011) and it will therefore not be 
considered any further. 
FGE Opinion adopted by 
EFSA 
Link No. of candidate 
substances 
FGE.76 31 January 2008 http://www.efsa.europa.eu/en/efsajournal/pub/875.htm 26 
FGE.76Rev1 24 October 2013  26 
 
The present revision of FGE.76, FGE.76Rev1, includes the consideration of one additional substance, 
5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004]. This substance is an α,β-unsaturated aldehyde 
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and was originally allocated to and evaluated in FGE.224 (EFSA CEF Panel, 2013) in which it was 
considered not to be of concern with respect to genotoxicity. 
In addition, toxicity data have now been provided for the substance 5,6-dihydro-2,4,6-tris(2-
methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113]. The data provided are a 14-day (Bauter, 2012) 
and a 90-day study (Bauter, 2013). 
Since the publication of FGE.76, information on European production figures has been provided by 
EFFA for eight substances, [FL-no: 15.002, 15.005, 15.008, 15.027, 15.029, 15.030, 15.109 and 
15.113] (EFFA, 2010; EFFA, 2012; EFFA, 2013a). Furthermore, new information from Industry on 
missing stereoisomeric composition for [FL-no: 15.022, 15.029, 15.030, 15.032, 15.109 and 15.113] 
(EFFA, 2013b) and information on solubility in water for [FL-no: 15.005, 15.008, 15.017, 15.018, 
15.019 and 15.113] ) (EFFA, 2013c) have also been included in the present revision.  
2. PRESENTATION OF THE SUBSTANCES IN THE JECFA FLAVOURING GROUP 
2.1. Description 
2.1.1. JECFA Status 
The JECFA has at its 59th meeting in 2002 evaluated a group of 30 flavouring substances consisting of 
sulphur-containing heterocyclic compounds (JECFA, 2002a; JECFA, 2003). 
2.1.2. EFSA Considerations 
Two of the 30 sulphur-containing heterocyclic compound are not in the Register [2-isobutyl-4,6-
dimethyldihydro-1,3,5-dithiazine and 4-isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine (mixture) 
(JECFA-no: 1046) and 2-isopropyl-4,6-dimethyldihydro-1,3,5-dithiazine and 4-isopropyl-2,6-
dimethyldihydro-1,3,5-dithiazine (mixture) (JECFA-no: 1047)]. One of the substances, 5-methyl-2-
thiophenecarbaldehyde [FL-no: 15.004], is an α,β-unsaturated aldehyde and one substance, 3-acetyl-
2,5-dimethylthiophene  [FL-no: 15.024], is an α,β-unsaturated ketone. These two substances were to 
be evaluated together with other α,β-unsaturated aldehydes and ketones. The α,β-unsaturated aldehyde 
5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004] was evaluated in FGE.224 (EFSA CEF Panel, 
2013) in which the substance was considered not to be of concern with respect to genotoxicity. The 
substance is therefore included in this revision of FGE.76. One substance [FL-no: 15.028] is no longer 
supported for use as a flavouring substance in Europe and will therefore not be considered any further. 
This consideration will therefore deals with 26 of the 30 JECFA evaluated substances.  
The Panel concluded that all the 26 substances in the JECFA flavouring group of sulphur-containing 
heterocyclic compounds are structurally related to the group of 59 thiazole, thiophene, thiazoline and 
thienyl derivatives from chemical group 29 and miscellaneous substances from chemical group 30 
evaluated by EFSA in the Flavouring Group Evaluation 21, Revision 3 (FGE.21Rev3)7 (EFSA CEF 
Panel, 2012). The substances in FGE.21Rev3 were subdivided into a number of subgroups, and the 
substances in this JECFA evaluated group will be considered in relation to their corresponding EFSA 
FGE.21Rev3 subgroup. 
                                                     
7  The Panel is aware that for FGE.21, a revision 4 has been released. For the candidate substances in subgroups B-II and B-III of  
 FGE.21Rev3, a concern with respect to genotoxicity was raised. This concern is also applicable to candidate substances [FL no: 15.029,  
 15.030 and 15.032] in FGE.76. Since in revision 4 of FGE.21 subgroup B-III has been removed, in order to facilitate the identification of  
 the reason for this concern for these three substances in FGE.76, reference to FGE.21Rev3 is maintained, rather than to FGE.21Rev4. 
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2.2. Isomers 
2.2.1. Status 
Six substances [FL-no: 15.022, 15.029, 15.030, 15.032, 15.109 and 15.113] in the group of JECFA 
evaluated sulphur-containing heterocyclic compounds have one or more chiral centres. Three of these 
substances can furthermore exist as geometrical isomers [FL-no: 15.029, 15.030 and 15.032]. 
2.2.2. EFSA Considerations 
Adequate information on isomeric composition is available for all six isomeric substances [FL-no: 
15.022, 15.029, 15.030, 15.032, 15.109 and 15.113] (Table 1). 
2.3. Specifications 
2.3.1. Status 
The JECFA specifications are available for all 26 substances (JECFA, 2002b). See Table 1. 
2.3.2. EFSA Considerations 
The available specifications are considered adequate for all 26 substances.  
3. INTAKE ESTIMATION 
3.1. Status 
For all substances evaluated through the JECFA Procedure, intake data are available for the EU (see 
Table 6).  
3.2. EFSA Considerations 
For all substances the Industry has submitted production figure for EU and therefore MSDI values for 
all can be calculated (see Table 6).  
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group of Sulphur-Containing Heterocyclic Compounds (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
15.001 
1052 
2-Mercaptothiophene S SH
 
3062 
478 
7774-74-5 
Liquid 
C4H4S2 
116.20 
Very slightly 
soluble 
Miscible 
166 
 
NMR 
98 % 
1.618-1.622 
1.250-1.255 
 
 
15.002 
1057 
2-Methyl-5-
methoxythiazole N
SO
 
3192 
736 
38205-64-0 
Liquid 
C5H7ONS 
129.18 
Insoluble 
Miscible 
117 (44 hPa) 
 
MS 
98 % 
1.515-1.520 
1.146-1.154 
 
 
15.004 
1050 
5-Methyl-2-
thiophenecarbaldehyde S
O
 
3209 
2203 
13679-70-4 
Liquid 
C6H6OS 
126.18 
Practically 
insoluble or 
insoluble 
Miscible 
113-114 (33hPa) 
 
NMR 
95 % 
1.574-1.586 
1.168-1.172 
 
 
15.005 
1039 
2,4-Dimethyl-5-
vinylthiazole N
S
 
3145 
2237 
65505-18-2 
Liquid 
C7H9NS 
139.22 
Slightly soluble 
Miscible 
183-184 
 
NMR 
99 % 
1.560-1.565 
1.050-1.056 
 
 
15.008 
1053 
2-Thienyl disulfide 
S S
S
S
 
3323 
2333 
6911-51-9 
Solid 
C8H6S4 
230.39 
Very soluble 
Soluble 
n.a. 
55-60 
NMR 
98 % 
n.a. 
n.a. 
 
 
15.011 
1055 
5-Acetyl-2,4-
dimethylthiazole 
N
S
O 3267 
2336 
38205-60-6 
Liquid 
C7H9ONS 
155.22 
Insoluble 
Miscible 
228-230 
 
NMR 
97 % 
1.536-1.547 
1.147-1.152 
 
 
15.013 
1034 
2-Isobutylthiazole 
N
S
 
3134 
11618 
18640-74-9 
Liquid 
C7H11NS 
141.24 
Slightly soluble 
Miscible 
178-180 
 
NMR 
96 % 
1.490-1.499 
0.993-0.997 
 
 
15.014 
1031 
5-(2-Hydroxyethyl)-4-
methylthiazole N
SHO
 
3204 
11621 
137-00-8 
Liquid 
C6H9ONS 
143.21 
Soluble 
Miscible 
135 (9 hPa) 
 
IR 
96 % 
1.540-1.556 
1.196-1.210 
 
 
15.015 
1054 
4-Methyl-5-(2-
acetoxyethyl)thiazole N
SO
O
 
3205 
11620 
656-53-1 
Liquid 
C8H11O2NS 
185.25 
Slightly soluble 
Miscible 
117-118 (8 hPa) 
 
NMR 
97 % 
1.505-1.515 
1.145-1.149 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group of Sulphur-Containing Heterocyclic Compounds (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
15.016 
1040 
Benzothiazole 
N
S
 
3256 
11594 
95-16-9 
Liquid 
C7H5NS 
135.19 
Very slightly 
soluble 
Miscible 
231 
 
NMR 
96 % 
1.637-1.644 
1.236-1.240 
 
 
15.017 
1035 
4,5-Dimethylthiazole 
N
S
 
3274 
11606 
3581-91-7 
Liquid 
C5H7NS 
113.18 
Very slightly 
soluble 
Miscible 
158 (965 hPa) 
 
NMR 
97 % 
1.516-1.524 
1.067-1.072 
 
 
15.018 
1038 
4-Methyl-5-vinylthiazole 
N
S
 
3313 
11633 
1759-28-0 
Liquid 
C6H7NS 
125.19 
Very slightly 
soluble 
Miscible 
78-80 (33 hPa) 
 
NMR 
97 % 
1.560-1.570 
1.091-1.095 
 
 
15.019 
1036 
2,4,5-Trimethylthiazole 
N
S
 
3325 
11650 
13623-11-5 
Liquid 
C6H9NS 
127.21 
Very slightly 
soluble 
Miscible 
65-67 (26 hPa) 
 
NMR 
97 % 
1.503-1.511 
1.011-1.015 
 
 
15.020 
1041 
2-Acetylthiazole 
N
S
O
 
3328 
11726 
24295-03-2 
Liquid 
C5H5ONS 
127.17 
Insoluble 
Miscible 
89-91 (16 hPa) 
 
NMR 
97 % 
1.543-1.550 
1.225-1.229 
 
 
15.021 
1056 
2-Ethoxythiazole 
N
S O
 
3340 
11611 
15679-19-3 
Liquid 
C5H7ONS 
129.18 
Insoluble 
Miscible 
157-160 
 
NMR 
99 % 
1.498-1.502 
1.131-1.135 
 
 
15.022 
1033 
2-(sec-Butyl)thiazole 
N
S
 
3372 
11598 
18277-27-5 
Liquid 
C7H11NS 
141.24 
Slightly soluble 
Miscible 
173-174 
 
NMR 
98 % 
1.496-1.502 
0.998-1.003 
 
Racemate (EFFA, 
2013b). 
15.026 
1037 
2-Isopropyl-4-
methylthiazole 
N
S
 
3555 
 
15679-13-7 
Liquid 
C7H11NS 
141.24 
Slightly soluble 
Miscible 
92 (65 hPa) 
 
NMR MS 
96 % 
1.480-1.502 
1.001-1.006 
 
 
15.027 
1042 
2-Propionylthiazole 
N
S
O
 
3611 
 
43039-98-1 
Liquid 
C6H7ONS 
141.19 
Insoluble 
Miscible 
95 (1 hPa) 
 
IR NMR MS 
98 % 
1.528-1.533 
1.205-1.210 
 
 
15.028 
1032 
Thiazole 
N
S
 
3615 
11642 
288-47-1 
Liquid 
C3H3NS 
85.13 
Slightly soluble 
Miscible 
115-118 
 
IR NMR MS 
98 % 
1.531-1.541 
1.198-1.202 
 
No longer supported 
by Industry (EFSA, 
2011). 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group of Sulphur-Containing Heterocyclic Compounds (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
15.029 
1059 
2-(sec-Butyl)-4,5-
dimethyl-3-thiazoline 
N
S
 
3619 
 
65894-82-8 
Liquid 
C9H17NS 
171.31 
Insoluble 
Miscible 
71 (5 hPa) 
 
IR NMR MS 
98 % 
1.483-1.488 
0.950-0.955 
 
According to JECFA: 
Min. assay value is 
”98 %” and ”60:40 
mix of cis and trans 
isomers”. Mixture of 
diastereoisomers, each 
of them racemic 
(EFFA, 2013b). 
15.030 
1058 
4,5-Dimethyl-2-ethyl-3-
thiazoline N
S
 
3620 
 
76788-46-0 
Liquid 
C7H13NS 
143.25 
Insoluble 
Miscible 
50 (4 hPa) 
 
IR NMR MS 
98 % 
1.490-1.495 
1.001-1.010 
 
Mixture of 
diastereoisomers, each 
of them racemic 
(EFFA, 2013b). 
15.032 
1045 
4,5-Dimethyl-2-isobutyl-3-
thiazoline N
S
 
3621 
 
65894-83-9 
Liquid 
C9H17NS 
171.31 
Insoluble 
Miscible 
71 (5 hPa) 
 
IR NMR MS 
97 % 
1.483-1.489 
0.933-0.937 
 
According to JECFA: 
Min. assay value is 
”97 %” and ”60:40 
mix of cis and trans 
isomers”. Mixture of 
diastereoisomers, each 
of them racemic 
(EFFA, 2013b). 
15.033 
1044 
2-Ethyl 4-methylthiazole 
N
S
 
3680 
11612 
15679-12-6 
Liquid 
C6H9NS 
127.21 
Slightly soluble 
Miscible 
161-162 
 
NMR MS 
97 % 
1.500-1.510 
1.026-1.031 
 
 
15.035 
1043 
4-Methylthiazole 
N
S
 
3716 
11627 
693-95-8 
Liquid 
C4H5NS 
99.16 
Slightly soluble 
Miscible 
133-134 
 
IR NMR MS 
97 % 
1.519-1.528 
1.088-1.092 
 
 
15.109 
1049 
2,4,6-Trimethyldihydro-
1,3,5(4H)-dithiazine S NH
S
 
4018 
11649 
638-17-5 
Solid 
C6H13NS2 
163.30 
Insoluble 
Miscible 
n.a. 
48 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
Mixture of 
diastereoisomers, each 
of them racemic 
(EFFA, 2013b). 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group of Sulphur-Containing Heterocyclic Compounds (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
15.113 
1048 
5,6-Dihydro-2,4,6,tris(2-
methylpropyl)-4H-1,3,5-
dithiazine 
S NH
S
 
4017 
 
74595-94-1 
Solid 
C15H31NS2 
289.55 
Slightly soluble 
Miscible 
n.a. 
33-35 
IR NMR 
95 % 
n.a. 
n.a. 
 
According to JECFA: 
Min. assay value is 
”95 % (mixture of 3 
stereoisomers).” 
Mixture of 
diastereoisomers, each 
of them racemic 
(EFFA, 2013b). 
16.027 
1030 
Thiamine hydrochloride 
+NH3
N+
S
N
N
HO
2 Cl-
3322 
10493 
67-03-8 
Solid 
C12H18ON4S 
337.27 
Soluble 
Slightly soluble 
n.a. 
248-250 
NMR 
98 % 
n.a. 
n.a. 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
n.a. Not applicable. 
 
F
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4. GENOTOXICITY DATA 
4.1. Genotoxicity Studies – Text Taken8 from the JECFA Report (JECFA, 2003) 
In Vitro 
Three substances, thiazole [FL-no: 15.028], 4,5-dimethylthiazole [FL-no: 15.017] and 4-
methylthiazole (FL-no: 15.035), in this group of flavouring substances were tested for their ability to 
induce reverse mutation in Salmonella typhimurium strains TA98 and TA100 at doses of 4 - 100 
µmol/plate. The purity of the chemicals was not stated. Positive results were obtained with thiazole in 
strain TA100 only at a minimum concentration of 4 µmol/plate; however, the mutagenicity that was 
observed in the absence of an exogenous metabolic activation system was less marked in the presence 
of such a system, indicating that thiazole does not undergo metabolic activation. The other substances 
gave uniformly negative results in both strains (Lee et al., 1994). No other tests have been reported. 
For a summary of in vitro genotoxicity data considered by the JECFA, see Table 2. 
4.2. Genotoxicity Studies – Text Taken9 from EFSA FGE.21Rev3 (EFSA CEF Panel, 
2012) 
In Vitro 
Genotoxicity data were provided for 12 of the candidate substances. These 12 substances belong to 
subgroup A-Ia: thiophene [FL-no: 15.106]; subgroup A-Ib: 2-methylthiophene [FL-no: 15.091], 3-
methylthiophene [FL-no: 15.092], 2,5-dimethylthiophene [FL-no: 15.064], 2-acetylthiophene [FL-no: 
15.040], 2-acetyl-3-methylthiophene [FL-no: 15.037], thiophene-2-carbaldehyde [FL-no: 15.107], 5-
ethylthiophene-2-carbaldehyde [FL-no: 15.074]; subgroup A-II: 2,4-dimethylthiazole [FL-no: 15.062]; 
subgroup A-III: 2-methyl-4,5-benzothiazole [FL-no: 15.088]; subgroup B-III: 2-methylthiazolidine 
[FL-no: 15.090] and 2-propylthiazolidine [FL-no: 15.099]. There were also mutagenicity data on four 
supporting substances and on four other structurally related substances. All available information on 
genotoxicity of the 12 candidate and the four supporting substances and of four other structurally 
related substances is based upon in vitro studies only. 
Subgroup A-I: 
Thiophene [FL-no: 15.106], 2-methylthiophene [FL-no: 15.091], 3-methylthiophene [FL-no: 15.092] 
and 2,5-dimethylthiophene [FL-no: 15.064] were reported to be negative in microbial mutagenicity 
assays. 2-Acetylthiophene [FL-no: 15.040] was negative in microbial tests, using Salmonella 
typhimurium strains TA98 and TA100, with and without metabolic activation and in the SOS 
chromotest with metabolic activation. 2-Acetylthiophene was reported to be positive without 
metabolic activation in the SOS Escherichia coli chromotest (Mosier et al., 2003). In the same study, 
2-acetyl-3-methylthiophene [FL-no: 15.037], thiophene-2-carbaldehyde [FL-no: 15.107] and 5-
ethylthiophene-2-carbaldehyde [FL-no: 15.074] gave positive results without metabolic activation in 
the SOS E. coli chromotest. The concentrations tested were not reported for any of the substances 
subjected to the SOS E. coli chromotest (Mosier et al., 2003). The Panel considered the endpoint of 
this test inappropriate for the estimation of genotoxic potential. The supporting substance 5-methyl-2-
thiophenecarbaldehyde [FL-no: 15.004] was negative in a microbial mutagenicity assay. 
Thiophene was tested in accordance with OECD guidelines in a bacterial reverse mutation test in 
strains of S. typhimurium and in strain WP2 uvrA of E. coli. No evidence of mutagenic response was 
reported when strains TA100, TA1535, TA98 and TA1537 of S. typhimurium were incubated at 
concentrations of 0, 78.1, 156, 313, 625, 1250, 2500 and 5000 μg/plate with and without S9 metabolic 
activation. Toxicity was observed at 1250 μg/plate in TA1537, and 2500 μg/plate in strains TA100, 
                                                     
8 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
9 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
F
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TA1535 and TA98 also with and without metabolic activation. Toxicity was observed at 5000 μg/plate 
in WP2 with and without S9 metabolic activation (Shibuya, 2006). 
In a chromosomal aberration test, thiophene was tested on Chinese hamster lung cells in accordance 
with Japanese Guidelines. No chromosomal aberrations or polyploidy was reported when incubated 
with concentrations of 0, 210, 420, 840 μg/mL of thiophene, with and without metabolic activity 
(Tanaka, 2006). 
Subgroup A-II: 
2,4-Dimethylthiazole [FL-no: 15.062] was reported to be negative in microbial assays, using S. 
typhimurium, but only in strain TA100 and only in the absence of metabolic activation (Voogd et al., 
1983). Two supporting substances, 4,5-dimethylthiazole [FL-no: 15.017] and 4-methylthiazole [FL-
no: 15.035], were negative in microbial mutagenicity assays. 
Subgroup A-III: 
2-Methyl-4,5-benzothiazole [FL-no: 15.088] was reported to be negative in an Ames test but only a 
summary report was available (Longfellow, 1998). The supporting substance benzothiazole [FL-no: 
15.016] was negative in microbial mutagenicity assay and in the mouse lymphoma test. 
Subgroups B-I and B-II: 
No genotoxicity information was available for any candidate or supporting substances in these 
subgroups. However, considering the structural similarities between the thiazolines in subgroup B-II 
and the thiazolidines in subgroup B-III, the Panel also concluded that the thiazolines [FL-no: 15.060, 
15.086 and 15.119] could not be evaluated through the Procedure (see Subgroup B-III below). 
Subgroup B-III: 
The two candidate substances 2-methylthiazolidine [FL-no: 15.090] and 2-propylthiazolidine [FL-no: 
15.099] as well as the structurally related ethyl, isopropyl, n-butyl and isobutyl thiazolidine have all 
been reported to be positive in the Ames tests (TA98 and TA100) (Mihara and Shibamoto, 1980). 
Owing to limited reporting, the data could not be properly evaluated. Nevertheless, these reports do 
raise the possibility of a genotoxic potential of these thiazolidines. Accordingly, it was concluded not 
to evaluate the candidate substances 2-methylthiazolidine and 2-propylthiazolidine through the 
Procedure. 
Subgroup B-IV:  
No genotoxicity information was available for any candidate or supporting substance in this subgroup.  
Subgroup B-V:  
The two candidate substances 6-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.114] (Register name: 5-
acetyl-2,3-dihydro-1,4-thiazine) and 5-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.133] are α,β-
unsaturated ketones i.e. they have a structural alert for genotoxicity (EFSA, 2008) and as there are no 
genotoxicity data available a concern for genotoxicity cannot be ruled out. 
Subgroup B-VI:  
No genotoxicity information was available for any candidate or supporting substance in this subgroup. 
Conclusion on genotoxicity 
F
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It is concluded that the genotoxicity data are limited and that genotoxicity could not be assessed 
adequately for the flavouring substances in the present revision of FGE.21, Revision 3. However, 
except for the two dihydrothiazines, 6-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.114] (Register 
name: 5-acetyl-2,3-dihydro-1,4-thiazine) and 5-acetyl-2,3-dihydro-1,4-thiazine [FL-no: 15.133], the 
two thiazolidines 2-methylthiazolidine [FL-no: 15.090] and 2-propylthiazolidine [FL-no: 15.099] and 
the three structurally related thiazolines 2-methyl-2-thiazoline [FL-no: 15.086], 2,4-dimethyl-3-
thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the genotoxicity data available 
do not preclude the evaluation of the remaining 49 candidate substances using the Procedure.  
For a summary of in vitro genotoxicity data considered by EFSA, see Table 3. 
4.3. Genotoxicity Studies and Conclusion on Genotoxicity and Carcinogenicity - 
Text Taken10 from FGE.224 (EFSA CEF Panel, 2013) 
The Industry has submitted data concerning genotoxicity studies for one substance, 5-methyl-2-
thiophenecarbaldehyde [FL-no: 15.004]. The new data submitted covers both in vitro and in vivo 
genotoxicity assays. 
In vitro data on 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004] 
Bacterial Reverse Mutation Assay 
5-Methyl-2-thiophenecarbaldehyde was tested for the induction of gene mutations in the Salmonella 
typhimurium strains TA98, TA100, TA1535, TA1537 and TA102 both in the absence and in the 
presence of Aroclor induced rat liver S9-mix. Three independent experiments were performed 
(Beevers, 2009). An initial toxicity range-finding experiment was carried out in the absence and 
presence of S9-mix in strain TA100. Six concentrations were tested in the concentration range 1.6 - 
5000 µg/plate of 5-methyl-2-thiophenecarbaldehyde. Negative (solvent) and positive controls were 
included. Toxicity, evident as a decrease in revertant count, was apparent on all plates treated at 1000 
µg/plate and above in the absence and presence of S9-mix, but revertant counts were obtained from at 
least four different concentrations, and these data were included as part of experiment 1. 
In the first main experiment, 5-methyl-2-thiophenecarbaldehyde was tested in the remaining 4 strains 
in the absence and presence of S9-mix using the plate incorporation methodology at concentrations 
ranging from 0.32 - 1000 µg/plate. Based on the range finding study the maximum tested 
concentration was reduced to 1000 µg/plate. Evidence of toxicity was observed at 200 μg/plate and 
above in strains TA1537 and TA102, in the presence of S9-mix, and at 1000 μg/plate in strains TA98 
and TA102 in the absence of S9-mix and in strains TA98 and TA1535 in the presence of S9-mix. 
However, revertant counts were obtained from six different concentrations, and so the data were 
considered valid for evaluation. 
In a second experiment, treatments of all the tester strains were performed in the absence and presence 
of S9-mix. For each strain the highest tested concentration was based on toxicity in the first 
experiment and narrowed concentration ranges were employed. In addition, all treatments in the 
presence of S9-mix were further modified by the inclusion of a 1-hour pre-incubation step. Clear 
evidence of toxicity was observed in strains TA98 and TA102 following treatment at the maximum 
test concentration in both the absence and presence of S9-mix, and in the strain TA1537 following 
treatment at the maximum concentration in the presence of S9-mix. However, toxicity was not seen at 
the concentrations tested in TA100 and TA1535 in the presence and absence of S9-mix or in TA1537 
in the absence of S9-mix, and therefore it was considered that higher concentrations should be 
evaluated. For the other strains data from a sufficient number of concentrations were obtained. 
                                                     
10 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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In the third experiment, 5-methyl-2-thiophenecarbaldehyde was tested in TA100 and TA1535 in the 
absence and presence of S9-mix and in TA1537 in the absence of S9-mix at 156.25 - 5000 µg/plate. 
Following these treatments, evidence of toxicity was observed at 2500 μg/plate and above in strains 
TA100 and TA1535 in the presence of S9-mix only. 
No statistically significant increases in revertant numbers were observed in any of the tester strains 
that were both concentration-related and clearly reproducible. Some small increases in revertant 
numbers were observed in strain TA1535 in the absence of S9-mix, but these were sporadic, not 
concentration related and not reproducible. They were therefore considered to be chance occurrences 
and not a compound-related effect and therefore not biological relevant. 
It was concluded that 5-methyl-2-thiophenecarbaldehyde did not induce mutation in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of S. typhimurium when tested under 
the conditions of this study. These conditions included treatments at concentrations up to either the 
limit of toxicity or 5000 μg/plate (the maximum recommended concentration according to current 
regulatory guidelines), in both the absence and in the presence of a rat liver metabolic activation 
system (S9-mix). 
For validation and study results, see Table 4. 
In Vitro Micronucleus assays 
5-Methyl-2-thiophenecarbaldehyde was tested for the induction of chromosome damage and potential 
aneugenic effects in an in vitro micronucleus assay using duplicate human peripheral blood 
lymphocytes prepared from pooled blood from two healthy volunteers in two separate experiments. 
Treatments were performed both in the absence and presence of Aroclor 1254 induced rat liver S9-mix 
(Lloyd, 2011). Experiment 1 was conducted using blood from female donors and Experiment 2 was 
conducted using blood from male donors. 
Treatment with 5-methyl-2-thiophenecarbaldehyde was conducted 48 hours following culture 
initiation (stimulation by phytohaemagglutinin). 
A preliminary toxicity range-finding experiment was conducted with S9-mix and 3 hours treatment 
and without S9-mix with 3 and 24 hours treatment. Toxicity was evaluated as the effect of treatment 
on the Replication Index (RI). Twelve concentrations from 4.6 to 1262 μg/mL were tested. The 
concentrations selected for the main experiments were based on toxicity data from this preliminary 
test. 
In experiment 1 (female donors), cells were exposed to 5-methyl-2-thiophenecarbaldehyde for 3 hours 
and 21 hours recovery (21 + 3) both with and without S9-mix. In addition, a continuous 24 hours 
treatment without recovery (24 + 0) was performed without S9 mix. All cultures were sampled 24 
hours after the beginning of treatment (i.e. 72 hours after culture initiation). The concentrations 
selected for evaluation in the absence of S9-mix and 3 hours exposure were 600, 900 and 1000 μg/mL 
and in the presence of S9-mix and 3 hours exposure 50, 60 and 70 μg/mL. After 24 hours exposure, 
cultures exposed to 120 μg/mL, 240 μg/mL, 300 μg/mL and 350 μg/mL were evaluated. Relevant 
positive and negative controls were included in all experiments. At the first test conditions (3 + 21 
hours without S9-mix) no significant increases in the frequency of micronucleated binucleate cells 
(MNBN) were observed relative to concurrent vehicle controls at all concentrations analysed. 
Furthermore, the MNBN cell frequencies in all treated cultures under this treatment condition fell 
within the 95th percentile of the normal range. 
In the 3 + 21 hours treatment condition with S9-mix the frequency of MNBN cells were significantly 
higher (1.05 %, 1.03 % and 1.33 % at 50, 60 and 70 μg/mL, respectively) (p ≤ 0.001) than concurrent 
controls (0.31 %) at all concentrations analysed. The initial analysis of 1000 binucleate cells/culture 
revealed increased MNBN cell frequencies that exceeded the 95th percentile of the normal range for 
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female donors in one of the two replicate cultures at 50 and 60 μg/mL and in both replicate cultures at 
70 μg/mL. Following the additional analysis of 1000 binucleate cells/culture from the vehicle controls 
and the test concentrations, the frequencies of MNBN cells were still significantly higher (p ≤ 0.001) 
than those observed in concurrent controls at all three concentrations analysed. The MNBN cell 
frequencies in one replicate culture at 60 μg/mL and in both replicate cultures at 70 μg/mL (1.33 %) 
exceeded the 95th percentile of the normal range (0.1 - 1.2 %), however, both cultures at 50 μg/mL 
(1.05 %) fell within the normal range. These observations are indicative of a weak induction of 
micronuclei.  
As a follow up of this positive result a second experiment was performed with lymphocytes from male 
donors to explore whether the weak induction of micronuclei that was observed in Experiment 1 in the 
presence of S9-mix could be due to the low MN frequencies in control cultures from female blood 
donors. Following treatment for 3 hours in the presence of S9-mix with 5-methyl-2-
thiophenecarbaldehyde at concentrations of 50 μg/mL, 60 μg/mL, 70 μg/mL and 80 μg/mL, followed 
by 21 hours recovery, and analysis of 1000 binucleate cells/culture, the frequencies of MNBN cells 
(0.9 %) were significantly higher (p ≤ 0.001) at 70 μg/mL compared to concurrent vehicle controls 
(0.30 %). The MNBN cell frequencies in single replicate cultures at 70 and 80 μg/mL exceeded the 
95th percentile of the normal range for male donors (0.0 - 0.7 %) but the MNBN frequency at 80 
μg/mL fell within the normal range. There was a concentration-dependent MN response from 50 - 70 
μg/mL, with 70 μg/mL exceeding the normal range (0.90 %). An additional 1000 binucleate 
cells/culture were analysed, and as a result of the additional scoring the MNBN cell frequencies were 
significantly higher (p ≤ 0.05) than concurrent vehicle controls at the three highest concentrations 
analysed (60, 70 and 80 μg/mL). However, the cumulative MNBN cell frequencies exceeded the 
normal range at only the 70.00 μg/mL concentration (and attributable to only one of two cultures). 
These results are again indicative of weak induction of micronuclei. 
In all of the different treatment conditions and separate experiments, negative control frequencies of 
MNBN were normal and were significantly increased by treatment with the positive control chemical.  
In conclusion, 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004] weakly induced micronuclei in 
both male and female human peripheral blood lymphocytes cultures when tested for 3 + 21 hours in 
the presence of S9-mix. In the same test system 5-methyl-2-thiophenecarbaldehyde did not induce 
micronuclei at up to toxic concentrations for 3 + 21 hours and 24 + 0 hours in the absence of S9-mix. 
For validation and study results, see Table 4. 
In Vivo data on 5-Methyl-2-thiophenecarbaldehyde [FL-no: 15.004] 
In Vivo Combination Assay (Comet + Micronucleus) 
On the basis of the in vitro micronucleus study reported above, as a next step to probe the genotoxic 
potential of 5-methyl-2-thiophenecarbaldehyde, a combined Comet assay and an in vivo micronucleus 
assay was carried out in rats (Beevers, 2012). This combined approach minimised the number of 
animals used in the experiments. Micronuclei were measured in bone marrow, but additionally, the 
liver was chosen as the most appropriate tissue for analysis in the Comet assay due to the fact that S9 
metabolic activation was necessary to produce weakly positive results in the in vitro micronucleus 
assay, and this organ is the primary site of metabolism. Therefore, groups of Han Wistar male rats 
were administered 5-methyl-2-thiophenecarbaldehyde via gavage and the liver and bone marrow were 
analysed for the potential induction of DNA damage. 
An initial dose range finding study was conducted to estimate the Maximum Tolerated Dose (MTD) of 
5-methyl-2-thiophenecarbaldehyde after administration by oral gavage to groups of three male and 
three female Han Wistar rats. Doses of 1000 mg/kg bw/day resulted in mortality in both male and 
female rats while at 700 mg/kg bw/day mortality occurred in the female group but not in the male 
group. On this basis, 700 mg/kg bw/day was considered the MTD in males and 500 mg/kg bw/day was 
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considered the MTD in females. Although there was a slight difference in MTD between males and 
females, it was less than 2-fold. Moreover, below 700 mg/kg bw/day no gender differences in clinical 
signs of toxicity were observed. It was therefore concluded that male rats alone could be used in the 
combined Comet and micronucleus assay. 
Groups of six male Han Wistar rats were treated by oral gavage with 5-methyl-2-
thiophenecarbaldehyde at doses of 70, 350 and 700 mg/kg bw/day, including a vehicle control (5 % 
w/v aqueous methylcellulose) and a positive control (ethyl methanesulphonate, 150 mg/kg bw/day). 
Animals were dosed at 0, 24 and 45 hours. Clinical signs of toxicity and body weight were recorded at 
each time point within the study. Three hours after the last dose (i.e. at 48 hours) the liver and one 
femur were removed from each control (negative and positive) and each treated animal for analysis of 
comets and micronuclei respectively. In a satellite group of animals (N = 3 per group) dosed similarly, 
0.5 mL samples of blood were taken from the jugular vein at 0.5, 1, 2, 4, 8 and 24 hours after the final 
dose in case bioanalytical proof of exposure was subsequently needed. 
No clinical signs of toxicity were observed for any animal in the treatment or control groups. No effect 
of treatment on body weight was observed. Clinical chemistry results did not present marked changes 
between treatment or control groups with two exceptions. Levels of aspartate aminotransferase were 
increased following dosing at 700 mg/kg bw/day compared to control values. Additionally, a 
histological observation of glycogen deposits in the liver of animals dosed at 350 and 700 mg/kg 
bw/day, along with changes in liver enzymes, indicate that the liver was exposed to the test article, 5-
methyl-2-thiophenecarbaldehyde. These observations indicated exposure to the target organ (the liver) 
of the Comet assay (see below).  
In the micronucleus assay femoral bone marrow was filtered through cellulose columns to remove 
the majority of nucleated cells, smears were made, fixed and stained with acridine orange. Two 
thousand polychromatic erythrocytes (PCE) per animal were scored for micronuclei under 
fluorescence microscopy. The data revealed that rats treated with 5-methyl-2-thiophenecarbaldehyde 
at all doses exhibited group mean % PCE (out of total erythrocytes) that were similar to the vehicle 
control group confirming there was no evidence of test article-related bone marrow toxicity. 
Micronucleus frequencies in vehicle control rats were normal and were significantly increased by 
positive control treatment. Rats treated with 5-methyl-2-thiophenecarbaldehyde at all doses exhibited 
micronuclei PCE frequencies that were similar to the vehicle control group and which were considered 
consistent with the laboratory's historical data. There were no statistically significant increases in 
micronucleus frequency for any of the groups receiving the test article, compared to the concurrent 
vehicle control. There was no evidence of bone marrow toxicity, and therefore no direct evidence that 
the substance did reach the bone marrow. Therefore, no firm conclusion could be drawn on this part of 
the study. 
In the alkaline Comet assay, liver samples from all control and test article treated animals were 
washed thoroughly, cut into small pieces in Merchants solution and then pushed through bolting cloth 
to produce single cell suspensions. Four slides were prepared per single cell suspension. Single cells 
were imbedded in agarose and once gelled, all slides were placed overnight in lysis buffer. Following 
lysis 3 of the 4 slides for each tissue and animal were transferred to electrophoresis buffer (pH >13) 
and the DNA unwound for 30 minutes and were electrophoresed in the same buffer at 0.7 V/cm for 40 
minutes. After the lysis step, the 4th slide from each tissue and animal was placed in pH 7.0 buffer for 
approximately 3 x 5 minutes and then dried. This ‘diffusion’ slide was used to estimate the degree of 
damaged cells in the cell suspensions. 
After staining with ethidium bromide tail moment and tail intensity (% DNA in tail) were obtained 
from 100 cells/animal/tissue (50 cells from each of two slides, where possible). Each slide was 
examined for possible indications of cytotoxicity. The number of 'clouds' out of 100 cells was scored 
for each slide. 'Clouds' were not used for comet analysis. Vehicle control animals exhibited quite low 
comet scores, but significant DNA damage was induced by the positive control. The Comet analysis 
revealed that animals treated with 5-methyl-2-thiophenecarbaldehyde exhibited elevated mean tail 
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intensities and tail moments compared to concurrent vehicle control animals. However, the majority of 
animals, including the vehicle controls, had tail intensity values below the laboratory’s historical 
control range and the elevated mean level was due to only one animal in each group. Thus, the data 
generated for this assay is considered to fall within the normal level of variation for the assay. In 
addition, there was no indication of dose response relationship. Therefore it is considered that 5-
methyl-2-thiophenecarbaldehyde does not induce DNA damage in the livers of rats when administered 
by oral gavage up to the MTD of 700 mg/kg bw/day. 
Although the Panel noted that the negative control values were extremely low (mean tail intensity of 
0.07) the assay was found acceptable because the positive control (EMS) was clearly positive (mean 
tail intensity of 29.43). The main problem with a low negative control value is that a test with low 
negative control values may have a difficulty to identify DNA crosslinking substances (with two 
reactive groups). However, the chemical structure of the test substance does not indicate a crosslinking 
potential. No studies on metabolism of 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004] are 
available to the Panel. The CEF Panel recently (EFSA CEF Panel, 2011) evaluated a structural related 
substance, 5-methyl furfural in FGE.66Rev1 (EFSA CEF Panel, 2011) to have no concern for 
genotoxicity. The most likely metabolic conversions of 5-methyl furfural [FL-no: 13.001] are 
oxidation of the aldehyde group to the carboxylic acid followed by conjugation with e.g. glycine or 
glucuronide, with rapid elimination in the urine. For furan and alkylfurans, ring opening has also been 
described, which would result in the formation of highly reactive unsaturated dialdehydes. In order to 
give an indication of whether ring opening could be possible for 5-methyl-2-thiophenecarbaldehyde 
[FL-no: 15.004] an “evaluation” of the metabolism of this substance was run in a prediction 
programme (METEOR NEXUS version 1.5). In this programme no indications of ring opening were 
generated. Overall the Panel considered that the formation of a bifunctional DNA reactive metabolite 
is unlikely, and therefore concludes that this substance is not likely to have a cross-linking potential. 
The negative result of the Comet assay in the liver is considered acceptable. 
For validation and study results, see Table 5. 
Conclusion on genotoxicity for 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004] 
5-Methyl-2-thiophenecarbaldehyde [FL-no: 15.004] did not induce mutations in a gene mutation test 
in bacteria (Ames test). It did, however, induce weak genotoxic effects in an in vitro micronucleus 
assay in the presence of S9-mix. However, these weakly positive in vitro results were not confirmed in 
an in vivo combination assay (Comet assay in liver + micronucleus in bone marrow) in male rats when 
dosed up to the MTD. The Panel therefore concluded that 5-methyl-2-thiophenecarbaldehyde [FL-no: 
15.004] does not give rise to concern with respect to genotoxicity and can accordingly be evaluated 
using the Procedure.  
For validation and study results, see Table 4 and 5. 
4.4. EFSA Considerations 
The Panel concluded that the three 3-thiazolines, 2-(sec-butyl)-4,5-dimethyl-3-thiazoline [FL-no: 
15.029], 4,5-dimethyl-2-ethyl-3-thiazoline [FL-no: 15.030] and 4,5-dimethyl-2-isobutyl-3-thiazoline 
[FL-no: 15.032] are structurally related to 2-methylthiazolidine [FL-no: 15.090] and 2-
propylthiazolidine [FL-no: 15.099], evaluated by the Panel in FGE.21Rev3 and reported to be positive 
in the Ames test (TA98 and TA100). In parallel with its conclusion on the subgroup B-II (thiazolines) 
in FGE.21Rev3, the Panel concluded that the Procedure could not be applied to these three thiazolines, 
[FL-no: 15,029, 15.030 and 15.032] until adequate in vivo genotoxicity data become available. 
Additionally, the Panel noted the presence of a terminal conjugated double bond in the substances 2,4-
dimethyl-5-vinylthiazole [FL-no: 15.005] and 4-methyl-5-vinylthiazole [FL-no: 15.018], which raised 
concern for genotoxicity. The Panel decided that the Procedure should not be applied to these two 
substances either until genotoxicity data become available due to the possibility of formation of 
reactive metabolites via epoxidation.  
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Based on the new in vitro and in vivo genotoxicity studies on 5-methyl-2-thiophenecarbaldehyde [FL-
no: 15.004], the Panel concluded in FGE.224 (EFSA CEF Panel, 2013) that 5-methyl-2-
thiophenecarbaldehyde does not give rise to concern with respect to genotoxicity and can accordingly 
be evaluated using the Procedure. 
The Panel concluded that the data available do not preclude evaluation of the remaining 21 JECFA 
evaluated sulphur-containing heterocyclic compounds through the Procedure. 
5. 14-DAY AND 90-DAY STUDY ON 5,6-DIHYDRO-2,4,6-TRIS(2-METHYLPROPYL)-4H-
1,3,5-DITHIAZINE [FL-NO: 15.113] 
A 14-day range-finding dietary study was performed with 5,6-dihydro-2,4,6-tris(2-methylpropyl)-
4H-1,3,5-dithiazine [FL-no: 15.113] (Bauter, 2012). The study was performed according to OECD 
Guideline (TG 407). Groups (3/sex/dietary intake level) of male and female Hsd:SD®  rats were fed a 
diet containing 0 (dietary control), 120, 1200 and 2400 mg 5,6-dihydro-2,4,6-tris(2-methylpropyl)-
4H-1,3,5-dithiazine per kg diet. These dietary levels were equivalent to daily intakes of 0, 11.3, 
111.2 and 217.0 mg/kg bw for males and 0, 11.2, 107.2 and 206.1 mg/kg bw for females, 
respectively. Clinical observations were recorded daily and body weights and food consumption 
observations were made on day 0, 7 and 14. No mortality was observed throughout the course of 
the study and the general condition of the rats was unremarkable. No gross pathology was related 
to the test-substance. 
A 90-day dietary study was performed with 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-
dithiazine [FL-no: 15.113] (Bauter, 2013). The study was performed according to OECD Guideline 
(TG 408). Four groups of rats (10/sex/dietary intake level) of male and female CRL Sprague-
Dawley CD®IGS rats were fed a diet containing 0 (dietary control) 140, 1050 and 2100 mg of 5,6-
dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine per kg diet. These dietary levels were 
equivalent to daily intakes of 0, 9.3, 67.9 and 131.9 mg/kg bw for males and 0, 11.0, 77.1 and 
153.7 mg/kg bw for females, respectively (Bauter, 2013). The animals were observed daily for signs 
of gross toxicity, viability and behavioural changes. Clinical observations of toxicity were 
performed on day 0 and weekly until sacrifice. Animals were weighed on day 0 at the start of the 
study and weekly thereafter. Food consumption and efficiency were measured and calculated weekly. 
Blood chemistry and haematology were performed on blood drawn via sublingual bleed during 
week 12 after overnight fast and coagulation assessment was performed prior to necropsy. Urine 
was collected during the 15 hours prior to the blood draw. Prior to initiation of the study and on 
day 91 the eyes of all rats were examined by focal illumination and indirect ophthalmoscopy. At 
termination of the study all animals were sacrificed and subject to full necropsy. The following 
tissues were weighed wet post dissection: adrenals, brain, epididymides, heart, kidneys, liver, ovaries, 
testes, spleen, thymus, uterus with oviducts. Histopathology was performed on a comprehensive 
number of tissues and organs in accordance with the guidelines. 
No mortality was observed in any group throughout the study. There were no toxicologically 
significant or dose-related differences in animals between treatment and control groups in food 
consumption or food efficiency, body weight and body weight gain, and clinical or 
ophthalmological parameters. Only a reduction in food consumption in females at the highest dose 
was reported to be statistically significant, which, however, was not accompanied with body weight 
changes and was not considered adverse or biologically relevant. No treatment-related differences in 
clinical or gross pathology or in organ weights were observed. Treatment-related microscopic  
findings were reported in the urinary bladder of males and females of the two highest dose groups 
(1050 and 2100 mg/kg diet) and involved statistically significant increase in the incidence of 
minimal to slight simple and diffuse hyperplasia of the mucosal epithelium with increased severity in 
the highest dose group. This finding was not correlated to any other clinical or pathological 
changes. 
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The author concluded that under the conditions of the study, the no-observed-adverse-effect level 
(NOAEL) for dietary administration of 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine 
was determined to be 140 m g / k g  diet, equivalent to an estimated daily intake of 9.3 mg/kg 
bw/day for males and 11.0 mg/kg bw/day for females, respectively, based on the effects noted on 
the urinary bladder. The Panel agrees to this conclusion and used 9.3 mg kg bw/day in the margin 
of safety assessment. 
6. APPLICATION OF THE PROCEDURE 
6.1. Application of the Procedure to 26 Sulphur-Containing Heterocyclic 
Compounds by the JECFA (JECFA, 2002a) 
According to the JECFA 17 of the substances belong to structural class II and nine to structural class 
III using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded on three sulphur-containing heterocyclic compounds [FL-no: 15.014, 15.015 
and 16.027] at step A3 in the JECFA Procedure, i.e. the substances are expected to be metabolised to 
innocuous products (step 2) and that the intakes for two of the substances [FL-no: 15.014 and 15.015] 
are below the thresholds for their structural class II (step A3). For one substance, thiamine 
hydrochloride [FL no: 16.027], the intake was above the threshold for structural class II and the 
substance is considered not to occur endogenously in humans, therefore the evaluation proceeded to 
step A5, where it was considered as of no safety concern at the estimated level of intake based on a 
90-day dietary study in rats in which a No Observed Adverse Effect Level (NOAEL) of 36 mg/kg 
body weight (bw)/day provides a margin of safety of more than 500. 
Twenty-three substances were concluded at step B4 in the JECFA Procedure, i.e. the substances are 
not expected to be metabolised to innocuous products and the estimated intakes are below the 
thresholds for their structural classes II and III. An adequate NOAEL was available for all 23 
substances and the JECFA concluded that the substances are therefore not expected to be of safety 
concern when used as flavouring substances. 
In conclusion, the JECFA evaluated all 26 substances to be of no safety concern at the estimated levels 
of intake as flavouring substances based on the MSDI approach. 
The evaluations of the 26 sulphur-containing heterocyclic compounds are summarised in Table 6: 
Summary of Safety Evaluation of Sulphur-Containing Heterocyclic Compounds (JECFA, 2003). 
6.2. Application of the Procedure to 59 Thiazoles, Thiophene, Thiazoline and Thienyl 
Derivatives and Miscellaneous Substances from Chemical Group 30 by EFSA 
(FGE.21Rev3) (EFSA CEF Panel, 2012) 
Fifty-nine candidate substances were evaluated in FGE.21Rev3. Fourty-eight substances are classified 
into structural class II and 11 into structural class III using the decision tree approach presented by 
(Cramer et al., 1978). 
For seven substances the Procedure could not be applied due to indication of genotoxic potential in 
vitro [FL-no: 15.060, 15.086, 15.090, 15.099, 15.114, 15.119 and 15.133]. 
The substances were allocated into structural subgroups (for description and explanation, see 
FGE.21Rev3) and were evaluated at step B4 in the Procedure, i.e. the substances are not expected to 
be metabolised to innocuous products and the estimated intakes are below the thresholds for their 
structural classes II and III. 
In summary, the Panel concluded that 26 of the candidate substances evaluated through the Procedure, 
from the structural subgroups A-Ic (thiophenes with thiol-containing ring substituents) and A-II 
(thiazoles) are not of safety concern at their estimated levels of intake based on the MSDI approach, 
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whereas for 26 candidate substances from the structural subgroups A-Ia  (thiophene), A-Ib  
(thiophenes with non-thiol-containing ring substituents), A-III (benzothiazoles), B-I 
(dihydrothiophenes), B-IV (dithiazines) and B-V (dihydrothiazines) additional data are required. 
The stepwise evaluations of the 59 substances are summarised in Table 7: Summary of Safety 
Evaluation Applying the Procedure (EFSA / FGE.21Rev3) (EFSA CEF Panel, 2012). 
6.3. EFSA Considerations 
The Panel agrees with the application of the Procedure, as performed by the JECFA, for 21 of the 26 
substances in the group of sulphur-containing heterocyclic compounds. Three of the 26 substances 
evaluated by the JECFA,  2-(sec-butyl)-4,5-dimethyl-3-thiazoline [FL-no: 15.029], 4,5-dimethyl-2-
ethyl-3-thiazoline [FL-no: 15.030] and 4,5-dimethyl-2-isobutyl-3-thiazoline [FL-no: 15.032] were 
considered by the Panel to have genotoxic potential in vitro, and therefore the Panel concluded that the 
Procedure should not be applied to these three flavouring substances until adequate in vivo 
genotoxicity data become available. Additionally, the Panel noted the presence of a terminal 
conjugated double bond in the substances 2,4-dimethyl-5-vinylthiazole [FL-no: 15.005] and 4-methyl-
5-vinylthiazole [FL-no: 15.018] which raised concern for genotoxicity. The Panel concluded, contrary 
to the JECFA, that the Procedure should not be applied to these two substances either until 
genotoxicity data become available. 
For the three substances [FL-no: 15.014, 15.015 and 16.027], expected to be metabolised to innocuous 
products (A-side), the Panel agrees with the JECFA evaluation. 
For 18 of the remaining 21 substances the Panel agreed with the JECFA that they can not be expected 
to be metabolised to innocuous products. The 18 substances were allocated to one of the 10 structural 
subgroups identified in FGE.21Rev3 (for description and explanation, see FGE.21Rev3). Taking these 
substances through the Procedure, it can be estimated that the intakes (MSDI) are below the thresholds 
for their structural classes II and III, and as the JECFA concluded that adequate NOAELs provides a 
sufficient safety margin, these substances were concluded at step B4 in the Procedure to be of no 
safety concern by the JECFA.  
For 16 of these 18 substances, from the structural subgroups: A-Ib (thiophenes with non-thiol-
containing ring substituents [FL-no:  5.004]), A-Ic (thiophenes with thiol-containing ring substituents 
[FL-no: 15.001 and 15.008]), A-II (thiazoles [FL-no: 15.002, 15.011, 15.013, 15.017, 15.019, 15.020, 
15.021, 15.022, 15.026, 15.027, 15.033 and 15.035]) and A-III  (benzothiazoles FL-no: 15.016]), the 
Panel agrees with the JECFA conclusion that these substances are not expected to be of safety concern 
when used as flavouring substances, as summarised in Table 6.  
For the remaining two of the 18 substances, 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-
dithiazine [FL-no: 15.113] and 2,4,6-trimethyldihydro-1,3,5(4H)-dithiazine [FL-no: 15.109] both from 
the structural subgroup B-IV (dithiazines), the intakes (MSDI) of 2.4 and 1.1 µg/capita/day, 
respectively, are below the threshold for their structural class II. The Panel considered that an adequate 
NOAEL of 9.3 mg/kg bw/day for [FL-no: 15.113] could be obtained from the new 90-day rat study, 
which at step B4 in the Procedure provides a sufficient safety margin of 2.3 x 105 for [FL-no: 15.113]. 
This NOAEL of 9.3 mg/kg bw/day for [FL-no: 15.113] can be used to support the structurally related 
2,4,6-trimethyldihydro-1,3,5(4H)-dithiazine [FL-no: 15.109], providing a safety margin of 5.1 x 105 
for [FL-no: 15.109]. So, it is concluded that these two flavouring substances, 5,6-dihydro-2,4,6-tris(2-
methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113] and 2,4,6-trimethyldihydro-1,3,5(4H)-dithiazine 
[FL-no: 15.109], were neither of safety concern, based on the MSDI approach.  
CONCLUSION 
In Flavouring Group Evaluation 76 (FGE.76), the EFSA considered 26 sulphur-containing 
heterocyclic compounds evaluated by the JECFA at its 59th meeting. Since publication of FGE.76 one 
substance, thiazole [FL-no: 15.028], is no longer supported by Industry for use as a flavouring 
F
 
EFSA Journal 2013;11(11):3455 26
substance in Europe and will therefore not be considered any further. The present revision is made due 
to inclusion of one additional substance, 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004], cleared 
for genotoxicity concern in FGE.224. Additionally, new toxicity data have become available for 5,6-
dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113]. Therefore, the present 
revision of FGE.76, FGE.76Rev1, considers 26 flavouring substances evaluated by the JECFA. 
In Flavouring Group Evaluation 76 (FGE.76), the EFSA considered 26 sulphur-containing 
heterocyclic compounds evaluated by the JECFA at its 59th meeting. Since publication of FGE.76, one 
substance, thiazole [FL-no: 15.028], is no longer supported by Industry for use as a flavouring 
substance in Europe and will therefore not be considered any further. The present revision is made due 
to inclusion of one additional substance, 5-methyl-2-thiophenecarbaldehyde [FL-no: 15.004], cleared 
for genotoxicity concern in FGE.224. Additionally, new toxicity data have become available for 5,6-
dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113]. Therefore, the present 
revision of FGE.76, FGE.76Rev1, considers 26 flavouring substances evaluated by the JECFA. 
The Panel concluded that all 26 Register substances in the JECFA flavouring group of sulphur-
containing heterocyclic compounds are structurally related to the 59 thiazoles, thiophene, thiazoline 
and thienyl derivatives from chemical group 29 and miscellaneous substances from chemical group 30 
evaluated by EFSA in the Flavouring Group Evaluation 21, Revision 3 (FGE.21Rev3).  
In the previous version of FGE.76, the Panel considered that for the substances [FL-no: 15.109 and 
15.113] no adequate NOAELs were available. Since then a 90-day study has become available for 5,6-
dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113] providing a NOAEL to 
establish adequate margins of safety for the substance as well as for the structurally related 2,4,6-
trimethyldihydro-1,3,5(4H)-dithiazine [FL-no: 15.109]. 
The Panel agrees with the application of the Procedure as performed by the JECFA for 21 of the 26 
substances considered in this FGE. Three of the remaining five substances,  2-(sec-butyl)-4,5-
dimethyl-3-thiazoline [FL-no: 15.029], 4,5-dimethyl-2-ethyl-3-thiazoline [FL-no: 15.030] and 4,5-
dimethyl-2-isobutyl-3-thiazoline [FL-no: 15.032] were considered by the Panel to have genotoxic 
potential in vitro, and therefore the Panel decided that the Procedure should not be applied to these 
three flavouring substances until adequate in vivo genotoxicity data become available. Additionally, 
the Panel noted the presence of a terminal conjugated double bond in the substances 2,4-dimethyl-5-
vinylthiazole [FL-no: 15.005] and 4-methyl-5-vinylthiazole [FL-no: 15.018] which raised concern for 
genotoxicity. The Panel concluded that the Procedure should not be applied to these two substances 
either until additional data become available. 
Thus, the Panel agreed that the Procedure can be applied to 21 of the 26 JECFA-evaluated substances 
[FL-no: 15.001, 15.002, 15.004, 15.008, 15.011, 15.013, 15.014, 15.015, 15.016, 15.017, 15.019, 
15.020, 15.021, 15.022, 15.026, 15.027, 15.033, 15.035, 15.109, 15.113 and 16.027], whereas the five 
substances [FL-no: 15.005, 15.018, 15.029, 15.030 and 15.032] cannot be evaluated using the 
Procedure until additional data become available. 
For all 21 substances evaluated through the Procedure use levels are needed to calculate the 
mTAMDIs in order to identify those flavouring substances that need more refined exposure 
assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the 26 JECFA-evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for all 26 JECFA-
evaluated substances. 
Thus, for five substances [FL-no:, 15.005, 15.018, 15.029, 15.030, 15.032,] the Panel could not 
conclude on their safety when used as flavouring substances as these substances could not be 
evaluated because of concern with respect to genotoxicity.].. 
F
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For the remaining 21 of JECFA-evaluated sulphur-containing heterocyclic compounds [FL-no: 
15.001, 15.002, 15.004, 15.008, 15.011, 15.013, 15.014, 15.015, 15.016, 15.017, 15.019, 15.020, 
15.021, 15.022, 15.026, 15.027, 15.033, 15.035, 15.109, 15.113 and 16.027] the Panel agrees with the 
JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances” based on 
the MSDI approach.  
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SUMMARY OF GENOTOXICITY DATA  
Table 2:  Genotoxicity Data (in vitro) for 30 Sulphur-Containing Heterocyclic Compounds Evaluated by the JECFA (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
 
1032 
Thiazole 
N
S
 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate  
(8513 µg/plate) 
Positive in 
TA100, 
negative in 
TA98; 
(±S9) 
(Lee et al., 1994) 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA1535; TA1537; 
TA1538; TA98; 
TA100 
Up to 10000 µg/plate Negative
(±S9) 
(Cameron et al., 1985) 
Mouse lymphoma assay Mouse 
L5178Y TK +/- 
1 - 6 µg/ml Negative
(±S9) 
(Cameron et al., 1985) 
15.017 
1035 
4,5-Dimethylthiazole 
N
S Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(11318 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) 
15.035 
1043 
4-Methylthiazole 
N
S Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9916 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) 
15.004 
1050 
5-Methyl-2-thiophenecarbaldehyde 
S
O Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(12,618 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.21Rev3 (EFSA CEF Panel, 2012) (substances in brackets are JECFA-evaluated substances) 
Chemical Name Test System Test Object Concentration Result  Reference  Comments 
Subgroup A-Ia 
Thiophene [15.106] Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
3 µmol/plate (all 
strains) 
(252 µg/plate) 
Negative
(±S9) 
(Florin et al., 1980) Published non-GLP study. Qualitative screening 
in a spot-test with three strains, quantitative 
study (4 doses, 0.03, 0.3, 3, 30 µmol/plate) with 
TA100 only. Limited report of experimental 
details and results. Insufficient quality, study not 
considered adequate for the evaluation of 
mutagenic activity. 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA97; TA98; 
TA100; TA1535; 
TA1537 
Up to 10,000 
µg/plate  
Negative 
(±S9)1 
(Zeiger et al., 1987) Non-GLP study roughly in accordance with 
OECD Guideline 471. The study is considered 
valid. 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.01 - 1.2 mmol/plate  
(100,968 µg/plate) 
Negative
(±S9) 
(Aeschbacher et al., 1989) Greatest effects are quantified by ”mutation 
factor,” no numbers are given for negative 
results. Limited quality (only 3 strains used), but 
otherwise acceptable study.  
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(8414 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable 
study. 
Ames assay S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
0, 78.1, 156, 313, 
625, 1250 µg/plate 
Negative
(±S9) 
(Shibuya, 2006) Valid study according to OECD Test Guidelines 
and Guidelines for screening mutagenicity 
testing of chemicals (Japan), provided as a 
translation of the original report in Japanese. 
 E. coli WP2 uvrA 0, 78.1, 156, 313, 
625, 1250, 2500, 
5000 µg/plate 
Negative
(±S9) 
  
Chromosomal 
Abberation 
Chinese hamster 
lung cells 
0, 210, 420, 840 
µg/ml 
Negative
(±S9) 
(Tanaka, 2006) Valid study according to Guidelines for 
screening mutagenicity testing of chemicals 
(Japan), provided as a translation of the original 
report in Japanese. 
Subgroup A-Ib 
2-Methylthiophene 
[15.091] 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.00001 - 1.0 
mmol/plate  
(98,170 µg/plate) 
Negative
(±S9) 
(Aeschbacher et al., 1989) Greatest effects are quantified by ”mutation 
factor,” no numbers are given for negative 
results. Limited quality (only 3 strains used), but 
otherwise acceptable study.  
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.21Rev3 (EFSA CEF Panel, 2012) (substances in brackets are JECFA-evaluated substances) 
Chemical Name Test System Test Object Concentration Result  Reference  Comments 
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9817 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable 
study. 
3-Methylthiophene 
[15.092] 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.01 - 1.0 mmol/plate  
(98170 µg/plate) 
Negative
(±S9) 
(Aeschbacher et al., 1989) Greatest effects are quantified by ”mutation 
factor,” no numbers are given for negative 
results. Limited quality (only 3 strains used), but 
otherwise acceptable study.  
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9817 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable 
study. 
2,5-Dimethylthiophene 
[15.064] 
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(11219 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable 
study. 
2-Acetylthiophene 
[15.040] 
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(12618 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable 
study. 
SOS Chromotest E. coli NR  Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation 
of genotoxic potential. 
2-Acetyl-3-
Methylthiophene [15.037] 
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation 
of genotoxic potential.  
Thiophene-2-carbaldehyde 
[15.107] 
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation 
of genotoxic potential. 
5-Ethylthiophene-2-
carbaldehyde [15.074] 
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation 
of genotoxic potential. 
(5-Methyl-2-
thiophenecarbaldehyde 
[15.004]) 
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(12618 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable 
study. 
Subgroup A-II 
2,4-Dimethylthiazole 
[15.062] 
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA100 
9.3 and 94 mmol/l 
top agar 
(10639 µg/ml) 
Negative
(-S9) 
(Voogd et al., 1983) Insufficient quality (one test strain as well as 
without metabolic activation only).  
(4,5-Dimethylthiazole 
[15.017]) 
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(11318 µg/plate) 
Negative
(±S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable 
study. 
(4-Methylthiazole Ames assay  S. typhimurium Up to 100 µmol/plate Negative (Lee et al., 1994) Only two strains used but otherwise acceptable 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.21Rev3 (EFSA CEF Panel, 2012) (substances in brackets are JECFA-evaluated substances) 
Chemical Name Test System Test Object Concentration Result  Reference  Comments 
[15.035]) (plate 
incorporation 
method) 
TA98; TA100 (9916 µg/plate) (±S9) study. 
Subgroup A-III 
2-Methyl-4,5-
benzothiazole [15.088] 
Ames assay  
(plate 
incorporation 
method) 
S. typhimurium 
TA98; TA100; 
TA102; TA1535; 
TA1537 
100 - 10000 µg/plate  Negative 
(±S9)1 
(Longfellow, 1998) Summary report of NCI-short-term test 
program, results not given in detail. 
(Benzothiazole [15.016]) Ames assay S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
Up to 5000 µg/plate   Negative
(±S9) 
(Bayer, 1991) Summary in IUCLID data set only. According 
to this summary, the assay was in compliance 
with GLP; accordance with OECD Guideline 
471 not stated. 
Mouse lymphoma 
assay 
Mouse 
L5178Y tk+/- cells 
10 - 250 µg/ml  Negative
(±S9) 
(Longfellow, 1997) Summary report of NCI-short-term test 
program, results not given in detail. 
Subgroup B-III 
2-Propylthiazolidine 
[15.099] 
Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 and 10 µg/ml: positive 
in TA100 (±S9); 
100 µg/ml: positive in 
TA98 and TA100.(±S9) 
(Mihara and Shibamoto, 
1980) 
The results were stated to be positive, however, 
the magnitude and a positive dose effect 
relationship could not be assessed (no numbers 
are given). 
2-Methylthiazolidine 
[15.090] 
Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 and 10 µg/ml: positive 
in TA100; (±S9) 
100 µg/ml: positive in 
TA98 and TA100 (±S9) 
(Mihara and Shibamoto, 
1980) 
The results were stated to be positive, however, 
the magnitude and a positive dose effect 
relationship could not be assessed (no numbers 
are given). 
(2-Ethylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 µg/ml: positive in 
TA100 (±S9) and TA98 
(-S9); 
10 µg/ml: positive in 
TA100 (±S9);  
100 µg/ml: positive 
TA98 and TA100.(±S9) 
(Mihara and Shibamoto, 
1980) 
The results were stated to be positive, however, 
the magnitude and a positive dose effect 
relationship could not be assessed (no numbers 
are given). 
(2-Isopropylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 and 10 µg/ml: positive 
in TA100 (±S9);  
100 µg/ml: positive in 
TA100 (±S9) and TA98 
(-S9) 
(Mihara and Shibamoto, 
1980) 
The results were stated to be positive, however, 
the magnitude and a positive dose effect 
relationship could not be assessed (no numbers 
are given). 
(2-Butylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 µg/ml: positive in 
TA100 (+S9);  
10 µg/ml: positive in 
TA100 (±S9);  
100 µg/ml: positive in 
TA100 (±S9) and TA98 
(Mihara and Shibamoto, 
1980) 
The results were stated to be positive, however, 
the magnitude and a positive dose effect 
relationship could not be assessed (no numbers 
are given). 
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Table 3:  Genotoxicity Data (in vitro) EFSA / FGE.21Rev3 (EFSA CEF Panel, 2012) (substances in brackets are JECFA-evaluated substances) 
Chemical Name Test System Test Object Concentration Result  Reference  Comments 
(-S9) 
(2-Isobutylthiazolidine) Ames assay S. typhimurium 
TA98; TA100 
1, 10, 100 µg/ml  1 µg/ml: positive in 
TA98 and TA100 
(+S9);  
10 µg/ml: positive in 
TA98 and TA100 
(±S9);  
100 µg/ml: positive in 
TA98 and TA100 (±S9)  
(Mihara and Shibamoto, 
1980) 
The results were stated to be positive, however, 
the magnitude and a positive dose effect 
relationship could not be assessed (no numbers 
are given). 
NR: Not Reported  
1: With and without rat and hamster S9 metabolic activation.  
 
 
No in vivo mutagenicity/genotoxicity data are available for the candidate substance of the present Flavouring Group Evaluation nor for the supporting 
substances evaluated by the JECFA at the 59th meeting. 
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Table 4:  Genotoxicity Data (in vitro). Summary of Additionally Genotoxicity Data on [FL-no: 15.004] of Subgroup 5.2 of FGE.19 
FL-no Chemical Name Test System in 
vitro  
Test Object  Concentrations of 
Substance and Test 
Conditions  
Result  Reference  Comments  
[15.004] 5-Methyl-2-
thiophenecarbaldehyde 
Reverse Mutation S. typhimurium TA98, 
TA1535, TA1537 and 
TA102 
 
S. typhimurium TA100 
0.32-1000 μg/plate 
[1,2]; 
 
1.6-5000 μg/plate 
[1,2] 
Negative (Beevers, 2009) Valid study performed in 
accordance with OECD Guideline 
471 and in compliance with GLP. 
S. typhimurium TA98a, 
TA100b, TA102c, 
TA1535d, and TA1537e 
10.24-1000 μg/plate 
[2,4,a,c,d,e]; 
10.24-1000 μg/plate 
[3,5,a,d]; 
25.6-2500 μg/plate 
[2,4,d,e]; 
4.096-400 μg/plate 
[3,5,b,c,e] 
Negative 
S. typhimurium TA100a, 
TA1535b, 
TA1537c 
156.25-5000 ug/plate 
[2,5,a,b]; 
156.25-5000 ug/plate 
[2,4,a,b,c]; 
Negative 
Micronucleus 
Assay 
Human peripheral blood 
lymphocytes (Female and 
Male Donors) 
600-1000 μg/ml [4,6]; 
50-70 μg/mL [5,6]; 
120-350 μg/mL [4,7]; 
50-80 μg/mL [5,6] 
Weak positive +S9. (Lloyd, 2011) Valid study performed in 
accordance with OECD Guideline 
471 and in compliance with GLP. 
[1] With and without S9 metabolic activation. 
[2] Plate incorporation method. 
[3] Pre-incubation method. 
[4] Without S9 metabolic activation. 
[5] With S9 metabolic activation. 
[6] 3-hour incubation with 21-hour recovery period. 
[7] 24-hour incubation with no recovery period. 
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Table 5:  Genotoxicity Data (in vivo). Summary of Additionally Genotoxicity Data on [FL-no: 15.004] of Subgroup 5.2 of FGE.19 
FL-no Chemical Name Test System in vivo  Test Object / 
Administration 
Concentrations of Substance 
and Test Conditions  
Result  Reference  Comments  
[15.004] 5-Methyl-2-
thiophenecarbaldehyde 
Micronucleus Assay 
in rat bone marrow 
Han Wistar rats (F+M) / 
Gavage 
70, 350 and 700 mg/kg bw/day 
(males only) 
Negative (Beevers, 2012) Valid study. In accordance with draft 
OECD Guideline 474 (2012), and in 
compliance with GLP. 
Top dose was the maximum tolerated. 
Systemic exposure indicated by liver 
function changes. 
Comet assay in rat 
liver 
Han Wistar rats (F+M) / 
Gavage 
70, 350 and 700 mg/kg bw/day 
(males only) 
Negative (Beevers, 2012) The study is in compliance with 
international accepted guidelines and in 
compliance with GLP.  
Top dose was maximum tolerated. 
Exposure to target organ indicated by 
liver function changes. 
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SUMMARY OF SAFETY EVALUATIONS 
Table 6:  Summary of Safety Evaluation of Sulphur-Containing Heterocyclic Compounds (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[4) or 5)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on the 
material of commerce 
15.014 
1031 
5-(2-Hydroxyethyl)-4-
methylthiazole N
SHO
 
150 
380 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.015 
1054 
4-Methyl-5-(2-
acetoxyethyl)thiazole N
SO
O
 
8.6 
3 
Class II 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.004 
1050 
5-Methyl-2-
thiophenecarbaldehyde S
O
 
0.73 
0.01 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) Evaluated in FGE.224, 
genotoxicity concern 
could be ruled out. No 
safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.005 
1039 
2,4-Dimethyl-5-
vinylthiazole N
S
 
0.012 
0.007 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) Genotoxicity data 
required. 
 
15.013 
1034 
2-Isobutylthiazole 
N
S
 
2.3 
0.4 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.017 
1035 
4,5-Dimethylthiazole 
N
S
 
0.18 
0.4 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.018 
1038 
4-Methyl-5-vinylthiazole 
N
S
 
2.1 
0.2 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
4) Genotoxicity data 
required. 
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Table 6:  Summary of Safety Evaluation of Sulphur-Containing Heterocyclic Compounds (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[4) or 5)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on the 
material of commerce 
exists 
15.019 
1036 
2,4,5-Trimethylthiazole 
N
S
 
0.61 
0.3 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.020 
1041 
2-Acetylthiazole 
N
S
O
 
9.7 
10 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.022 
1033 
2-(sec-Butyl)thiazole 
N
S
 
0.024 
0.01 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.026 
1037 
2-Isopropyl-4-
methylthiazole 
N
S
 
19 
10 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.027 
1042 
2-Propionylthiazole 
N
S
O
 
0.056 
0.2 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.028 
1032 
Thiazole 
N
S
 
0.012 
0.07 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No longer supported by 
Industry (EFSA, 2011). 
No longer supported by 
Industry (EFSA, 2011). 
15.033 
1044 
2-Ethyl 4-methylthiazole 
N
S
 
3.2 
1 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.035 
1043 
4-Methylthiazole 
N
S
 
0.097 
0.05 
Class II 
B3: Intake below 
threshold,  
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
No safety concern at the 
estimated level of intake 
based on the MSDI 
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Table 6:  Summary of Safety Evaluation of Sulphur-Containing Heterocyclic Compounds (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[4) or 5)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on the 
material of commerce 
B4: Adequate NOAEL 
exists 
approach. approach. 
15.109 
1049 
2,4,6-Trimethyldihydro-
1,3,5(4H)-dithiazine S NH
S
 
1.1 
3.3 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.113 
1048 
5,6-Dihydro-2,4,6,tris(2-
methylpropyl)-4H-1,3,5-
dithiazine 
S NH
S
 
2.4 
2.6 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
16.027 
1030 
Thiamine hydrochloride 
+NH3
N+
S
N
N
HO
2 Cl-  
300 
1200 
Class II 
A3: Intake above 
threshold,  
A4: Not endogenous,  
A5: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.001 
1052 
2-Mercaptothiophene S SH
 
0.012 
0.03 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.002 
1057 
2-Methyl-5-
methoxythiazole N
SO
 
0.012 
0.01 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.008 
1053 
2-Thienyl disulfide 
S S
S
S
 
0.061 
0.07 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.011 
1055 
5-Acetyl-2,4-
dimethylthiazole 
N
S
O
 
0.012 
2 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Flavouring Group Evaluation 76, Revision 1
 
EFSA Journal 2013;11(11):3455 38
Table 6:  Summary of Safety Evaluation of Sulphur-Containing Heterocyclic Compounds (JECFA, 2003) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound 
[4) or 5)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, genotoxicity) 
EFSA conclusion on the 
material of commerce 
15.016 
1040 
Benzothiazole 
N
S
 
1.2 
0.2 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.021 
1056 
2-Ethoxythiazole 
N
S O
 
0.012 
0.12 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
15.029 
1059 
2-(sec-Butyl)-4,5-
dimethyl-3-thiazoline 
N
S
 
0.012 
5 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) Genotoxicity data 
required. 
 
15.030 
1058 
4,5-Dimethyl-2-ethyl-3-
thiazoline N
S
 
0.012 
0.01 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) Genotoxicity data 
required. 
 
15.032 
1045 
4,5-Dimethyl-2-isobutyl-
3-thiazoline N
S
 
0.012 
4 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) Genotoxicity data 
required. 
 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.037 
 
2-Acetyl-3-
methylthiophene S
O 0.18 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.038 
 
2-Acetyl-4-methylthiazole 
N
S
O 0.0049 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.039 
 
2-Acetyl-5-methylthiazole 
N
S
O 0.0024 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.040 
 
2-Acetylthiophene 
S
O 2.2 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.043 
 
2-Butyl-5-ethylthiophene S
 
0.0012 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.044 
 
2-Butylthiazole 
N
S
 
0.011 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.045 
 
2-Butylthiophene S
 
0.012 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.050 
 
2,5-Diethyl-4-
methylthiazole 
N
S
 
0.012 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.051 
 
2,5-Diethyl-4-
propylthiazole 
N
S 0.0012 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.052 
 
2,5-Diethylthiazole 
N
S
 
0.015 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.054 
 
Dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine 
S NH
S 0.0012 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.058 
 
4,5-Dimethyl-2-
ethylthiazole 
N
S
 
0.015 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.061 
 
2,5-Dimethyl-4-
ethylthiazole 
N
S
 
0.011 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.062 
 
2,4-Dimethylthiazole 
N
S
 
0.61 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.063 
 
2,5-Dimethylthiazole 
N
S
 
0.0061 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.064 
 
2,5-Dimethylthiophene S
 
0.23 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.067 
 
4-Ethyl-2-methylthiazole 
N
S
 
0.0037 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.068 
 
5-Ethyl-2-methylthiazole 
N
S
 
0.0061 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.069 
 
4-Ethyl-5-methylthiazole 
N
S
 
0.012 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.070 
 
2-Ethyl-5-methylthiophene S
 
0.061 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.071 
 
2-Ethylthiazole 
N
S
 
0.028 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.072 
 
2-Ethylthiophene S
 
0.0012 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.074 
 
5-Ethylthiophene-2-
carbaldehyde S
O 0.0012 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.076 
 
2-Hexylthiophene S
 
0.12 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.078 
 
2-Isobutyl-4,5-
dimethylthiazole 
N
S
 
0.12 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.080 
 
2-Isopropyl-4,5-
dimethylthiazole 
N
S
0.012 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.084 
 
5-Methyl-2-pentylthiazole 
N
S
 
0.0037 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.085 
 
4-Methyl-2-
propionylthiazole 
N
S
O 0.0037 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.089 
 
2-Methylthiazole 
N
S
 
0.018 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.091 
 
2-Methylthiophene S
 
0.019 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.092 
 
3-Methylthiophene S
 
0.12 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.093 
 
2-Octylthiophene S 0.012 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.094 
 
2-Pentanoylthiophene 
S
O 0.0012 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.096 
 
sec-Pentylthiophene S
 
0.24 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.097 
 
2-Propionylthiophene 
S
O 0.12 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.098 
 
2-Propylthiazole 
N
S
 
0.085 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.107 
 
Thiophene-2-carbaldehyde 
S
O 0.21 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.115 
 
2-Isobutyl-4-methyl 
thiazole 
N
S
 
0.011 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.116 
 
2-Acetyl-4-ethylthiazole 
N
S
O 0.024 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.118 
 
4-Butylthiazole 
N
S 1.3 
 
Class II 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.129 
 
Tetrahydro-2,4,6-
trimethyl-1,3,5(2H)-
thiadiazine HN NH
S 0.61 
 
Class II 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.060 
 
2,4-Dimethyl-3-thiazoline 
N
S 0.012 
 
Class II 
No evaluation 
  b) 
15.086 
 
2-Methyl-2-thiazoline 
N
S 0.24 
 
Class II 
No evaluation 
  b) 
15.090 
 
2-Methylthiazolidine 
NH
S 0.024 
 
Class II 
No evaluation 
  c) 
15.099 
 
2-Propylthiazolidine 
NH
S 0.012 
 
Class II 
No evaluation 
  c) 
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.119 
 
2-Isobutyl-3-thiazoline 
N
S 0.011 
 
Class II 
No evaluation 
  b) 
15.042 
 
2-Butyl-4-
methyl(4H)pyrrolidino[1,2
d]-1,3,5-dithiazine S N
S 0.0012 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.055 
 
2,4-
Dimethyl(4H)pyrrolidino[
1,2e]-1,3,5-dithiazine S N
S
0.055 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.057 
  
4,6-Dimethyl-2-(1-
methylethyl)dihydro-1,3,5-
dithiazine S
N
H
S
1.5 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.077 
 
4-Hydroxy-2,5-
dimethylthiophen-3(2H)-
one 
S
HO O
0.12 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.079 
 
2-Isobutyldihydro-4,6-
dimethyl-1,3,5-dithiazine 
S
N
H
S
5.7 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.082 
 
3-Mercaptothiophene S
SH  
0.011 
 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
Flavouring Group Evaluation 76, Revision 1
 
EFSA Journal 2013;11(11):3455 46
Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) (EFSA/FGE.21Rev3) (EFSA 
CEF Panel, 2012) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
15.087 
 
2-Methyl-3-
mercaptothiophene 
S
SH  
0.12 
 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.088 
 
2-Methyl-4,5-
benzothiazole 
N
S
 
0.0085 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required  a) 
15.106 
 
Thiophene S
 
0.12 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.108 
 
2-Thiophenemethanethiol S
SH
 
0.0073 
 
Class III 
B3: Intake below 
threshold,  
B4: Adequate NOAEL 
exists 
4) 6)  
15.135 
 
Ethyl thialdine 
S
N
H
S
0.61 
 
Class III 
B3: Intake below 
threshold,  
B4: No adequate NOAEL 
Additional data required   
15.114 
 
5-Acetyl-2,3-dihydro-1,4-
thiazine 
N
H
S
O 0.012 
 
Class III 
No evaluation 
  c) 
15.133 
 
5-Acetyl-2,3-dihydro-1,4-
thiazine 
S
N
H
O
0.61 
 
Class III 
No evaluation 
  c) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
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3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on 
stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) Substance not supported by Industry (EFFA, 2009). 
b) Genotoxic potential in vitro. 
c) Genotoxic potential in vitro. Substance not supported by Industry (EFFA, 2009). 
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ABBREVIATIONS 
BW  body weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE  Council of Europe 
DNA  deoxyribonucleic acid 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  good laboratory practice 
ID  identity 
IR  infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MNBN  micronucleated binucleate cells 
MSDI  maximised survey-derived daily intake 
mTAMDI modified theoretical added maximum daily intake 
MTD  maximum tolerated dose 
NCE  normochromatic erythrocyte 
No  number 
NOAEL no observed adverse effect level 
OECD  Organization for Economic Cooperation and Development  
PCE  polychromatic erythrocyte 
RI  replication index 
SCF  Scientific Committee on Food 
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WHO  World Health Organisation 
